Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 1.75T |
| Revenue (ttm) | 1.57T |
| Net Income (ttm) | 195.86B |
| Shares Out | 11.51M |
| EPS (ttm) | 17,021.64 |
| PE Ratio | 8.92 |
| Forward PE | 10.54 |
| Dividend | 600.00 (0.40%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 26,530 |
| Average Volume | 31,641 |
| Open | 150,000 |
| Previous Close | 149,600 |
| Day's Range | 148,800 - 152,600 |
| 52-Week Range | 128,400 - 199,400 |
| Beta | 0.16 |
| RSI | 46.12 |
| Earnings Date | May 15, 2026 |
About Daewoong Pharmaceutical
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ... [Read more]
Financial Performance
In 2025, Daewoong Pharmaceutical's revenue was 1.57 trillion, an increase of 10.42% compared to the previous year's 1.42 trillion. Earnings were 195.86 billion, an increase of 691.83%.
Financial StatementsNews
Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis
Sun Pharmaceutical Industries Limited has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, a novel treatment for Erosive Esophagitis. FEXUCLUE® is a Potassium-Competitive Acid Bl...